Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Orzel, Andrew
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS	Recruiting	2/3	230	Canada, US	MN-166, ibudilast, placebo	MediciNova	Amyotrophic Lateral Sclerosis	12/25	12/26
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol	Active, not recruiting	2/3	1500	US	Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343	Merit E. Cudkowicz, MD, Massachusetts General Hospital	Amyotrophic Lateral Sclerosis	07/25	04/26
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial	Active, not recruiting	N/A	2486	Europe, Canada, US, RoW	Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS	Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)	Carotid Stenosis	02/26	02/26